{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:22:58Z","timestamp":1787761378589,"version":"build-2784847793"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.7759\/cureus.55459","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:47:46Z","timestamp":1709534866000},"source":"Crossref","is-referenced-by-count":5,"title":["The Efficacy and Safety of Biologics in Treating Ankylosing Spondylitis and Their Impact on Quality of Life and Comorbidities: A Literature Review"],"prefix":"10.7759","author":[{"given":"Abdulrahman","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danah","family":"Albarrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Alammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados M","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011, 377:2127-37. 10.1016\/S0140-6736(11)60071-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015872","article-title":"Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database","volume":"7","author":"Bhoi P","year":"2017","unstructured":"Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017, 7:e015872. 10.1136\/bmjopen-2017-015872","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk C","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015, 74:65-73. 10.1136\/annrheumdis-2013-203582","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-008-0060-3","article-title":"Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review","volume":"10","author":"Akkoc N","year":"2008","unstructured":"Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep. 2008, 10:371-8. 10.1007\/s11926-008-0060-3","journal-title":"Curr Rheumatol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014, 53:650-7. 10.1093\/rheumatology\/ket387","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61 Suppl 3","author":"Sieper J","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002, 61 Suppl 3:iii8-18. 10.1136\/ard.61.suppl_3.iii8","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.109164","article-title":"Ankylosing spondylitis pathogenesis and pathophysiology","author":"Alexander M","year":"2023","unstructured":"Alexander M. Ankylosing spondylitis pathogenesis and pathophysiology. Ankylosing spondylitis - recent concepts. Armas JB (ed): IntechOpen, London, UK; 2023. 1-33. 10.5772\/intechopen.109164"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2002.0244","article-title":"Ankylosing spondylitis: what is the cost to society, and can it be reduced?","volume":"16","author":"Boonen A","year":"2002","unstructured":"Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced?. Best Pract Res Clin Rheumatol. 2002, 16:691-705. 10.1053\/berh.2002.0244","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401015","article-title":"Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment","volume":"40","author":"Brown MA","year":"1997","unstructured":"Brown MA, Kennedy LG, MacGregor AJ, et al.. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997, 40:1823-8. 10.1002\/art.1780401015","journal-title":"Arthritis Rheum"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2662-7","article-title":"An update on the contribution of the MHC to AS susceptibility","volume":"33","author":"Reveille JD","year":"2014","unstructured":"Reveille JD. An update on the contribution of the MHC to AS susceptibility. Clin Rheumatol. 2014, 33:749-57. 10.1007\/s10067-014-2662-7","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.07.013","article-title":"HLA-B27 misfolding and ankylosing spondylitis","volume":"57","author":"Colbert RA","year":"2014","unstructured":"Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol. 2014, 57:44-51. 10.1016\/j.molimm.2013.07.013","journal-title":"Mol Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100889","article-title":"The role of HLA-B27 in spondyloarthritis","volume":"37","author":"Taurog JD","year":"2010","unstructured":"Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol. 2010, 37:2606-16. 10.3899\/jrheum.100889","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.38644","article-title":"HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis","volume":"66","author":"Jeanty C","year":"2014","unstructured":"Jeanty C, Sourisce A, Noteuil A, et al.. HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis. Arthritis Rheumatol. 2014, 66:2113-23. 10.1002\/art.38644","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","author":"Cortes A","year":"2013","unstructured":"Cortes A, Hadler J, Pointon JP, et al.. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013, 45:730-8. 10.1038\/ng.2667","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03701-3","article-title":"Genome-wide association study reveals ethnicity-specific SNPs associated with ankylosing spondylitis in the Taiwanese population","volume":"20","author":"Ko CL","year":"2022","unstructured":"Ko CL, Lin WZ, Lee MT, et al.. Genome-wide association study reveals ethnicity-specific SNPs associated with ankylosing spondylitis in the Taiwanese population. J Transl Med. 2022, 20:589. 10.1186\/s12967-022-03701-3","journal-title":"J Transl Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses","volume":"108","author":"Sarin R","year":"2011","unstructured":"Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA. 2011, 108:9560-5. 10.1073\/pnas.1017854108","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans DM","year":"2011","unstructured":"Evans DM, Spencer CC, Pointon JJ, et al.. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011, 43:761-7. 10.1038\/ng.873","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133322","article-title":"Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese","volume":"70","author":"Davidson SI","year":"2011","unstructured":"Davidson SI, Liu Y, Danoy PA, et al.. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Ann Rheum Dis. 2011, 70:289-92. 10.1136\/ard.2010.133322","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.09.003","article-title":"Cytokines that regulate autoimmunity","volume":"20","author":"Diveu C","year":"2008","unstructured":"Diveu C, McGeachy MJ, Cua DJ. Cytokines that regulate autoimmunity. Curr Opin Immunol. 2008, 20:663-8. 10.1016\/j.coi.2008.09.003","journal-title":"Curr Opin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"202","author":"Langrish CL","year":"2004","unstructured":"Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004, 202:96-105. 10.1111\/j.0105-2896.2004.00214.x","journal-title":"Immunol Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh A","year":"2018","unstructured":"Rezaiemanesh A, Abdolmaleki M, Abdolmohammadi K, et al.. Immune cells involved in the pathogenesis of ankylosing spondylitis. Biomed Pharmacother. 2018, 100:198-204. 10.1016\/j.biopha.2018.01.108","journal-title":"Biomed Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz SG","year":"2001","unstructured":"Hymowitz SG, Filvaroff EH, Yin JP, et al.. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001, 20:5332-41. 10.1093\/emboj\/20.19.5332","journal-title":"EMBO J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.30593","article-title":"Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response","volume":"63","author":"Zeng L","year":"2011","unstructured":"Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum. 2011, 63:3807-17. 10.1002\/art.30593","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen SL","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014, 14:585-600. 10.1038\/nri3707","journal-title":"Nat Rev Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Reveille JD","year":"2010","unstructured":"Reveille JD, Sims AM, Danoy P, et al.. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010, 42:123-7. 10.1038\/ng.513","journal-title":"Nat Genet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/art.38638","article-title":"Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham H","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, et al.. Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014, 66:1755-67. 10.1002\/art.38638","journal-title":"Arthritis Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac005","article-title":"Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis","volume":"33","author":"Min HK","year":"2023","unstructured":"Min HK, Kim HR, Lee SH, Hong YS, Kim MY, Park SH, Kang KY. Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis. Mod Rheumatol. 2023, 33:194-201. 10.1093\/mr\/roac005","journal-title":"Mod Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu W","year":"2019","unstructured":"Zhu W, He X, Cheng K, et al.. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019, 7:22. 10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216741","article-title":"Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence","volume":"79","author":"Koo BS","year":"2020","unstructured":"Koo BS, Oh JS, Park SY, et al.. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis. 2020, 79:1327-32. 10.1136\/annrheumdis-2019-216741","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny S","year":"2012","unstructured":"Glatigny S, Fert I, Blaton MA, Lories RJ, Araujo LM, Chiocchia G, Breban M. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012, 64:110-20. 10.1002\/art.33321","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock JP","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, et al.. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012, 18:1069-76. 10.1038\/nm.2817","journal-title":"Nat Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen H","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009, 60:1647-56. 10.1002\/art.24568","journal-title":"Arthritis Rheum"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness P","year":"2011","unstructured":"Bowness P, Ridley A, Shaw J, et al.. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011, 186:2672-80. 10.4049\/jimmunol.1002653","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna TJ","year":"2012","unstructured":"Kenna TJ, Davidson SI, Duan R, et al.. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012, 64:1420-9. 10.1002\/art.33507","journal-title":"Arthritis Rheum"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel H","year":"2011","unstructured":"Appel H, Maier R, Wu P, et al.. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011, 13:R95. 10.1186\/ar3370","journal-title":"Arthritis Res Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos T","year":"2012","unstructured":"Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Ca\u0148ete JD, Baeten D. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012, 64:99-109. 10.1002\/art.33396","journal-title":"Arthritis Rheum"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8316106","article-title":"Optimal biologic drugs for the treatment of ankylosing spondylitis: results from a network meta-analysis and network metaregression","volume":"2022","author":"Cao Z","year":"2022","unstructured":"Cao Z, Guo J, Li Q, Li Y, Wu J. Optimal biologic drugs for the treatment of ankylosing spondylitis: results from a network meta-analysis and network metaregression. Biomed Res Int. 2022, 2022:8316106. 10.1155\/2022\/8316106","journal-title":"Biomed Res Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04970-3","article-title":"A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis","volume":"39","author":"Deodhar A","year":"2020","unstructured":"Deodhar A, Chakravarty SD, Cameron C, et al.. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020, 39:2307-15. 10.1007\/s10067-020-04970-3","journal-title":"Clin Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten D","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al.. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015, 373:2534-48. 10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014, 371:326-38. 10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003060","article-title":"Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis","volume":"95","author":"Chen C","year":"2016","unstructured":"Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore). 2016, 95:e3060. 10.1097\/MD.0000000000003060","journal-title":"Medicine (Baltimore)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0246-6","article-title":"Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis","volume":"35","author":"Migliore A","year":"2015","unstructured":"Migliore A, Bizzi E, Bernardi M, Picchianti Diamanti A, Lagan\u00e0 B, Petrella L. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig. 2015, 35:23-9. 10.1007\/s40261-014-0246-6","journal-title":"Clin Drug Investig"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket249","article-title":"Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study","volume":"52","author":"Spadaro A","year":"2013","unstructured":"Spadaro A, Lubrano E, Marchesoni A, et al.. Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study. Rheumatology (Oxford). 2013, 52:1914-9. 10.1093\/rheumatology\/ket249","journal-title":"Rheumatology (Oxford)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1325034","article-title":"The risk of herpes zoster in patients with ankylosing spondylitis: analysis of the Korean National Health Insurance Service - sample cohort database","volume":"28","author":"Lim DH","year":"2018","unstructured":"Lim DH, Kim YJ, Kim SO, Hong S, Lee CK, Yoo B, Kim YG. The risk of herpes zoster in patients with ankylosing spondylitis: analysis of the Korean National Health Insurance Service - sample cohort database. Mod Rheumatol. 2018, 28:168-73. 10.1080\/14397595.2017.1325034","journal-title":"Mod Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1348","article-title":"The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?","volume":"59","author":"Wro\u0144ski J","year":"2019","unstructured":"Wro\u0144ski J, Fiedor P. The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?. J Clin Pharmacol. 2019, 59:445-62. 10.1002\/jcph.1348","journal-title":"J Clin Pharmacol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.09.063","article-title":"Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2b randomized, placebo-controlled trial","volume":"121","author":"Beck L","year":"2018","unstructured":"Beck L, Hong C, Hu X, Chen S, Calimlim B, Teixeira H, Guttman-Yassky E. Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2b randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2018, 121:S21. 10.1016\/j.anai.2018.09.063","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest","volume":"52","author":"Sandborn W","year":"2017","unstructured":"Sandborn W, Feagan B, Panes J, et al.. Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest. United European Gastroenterol J. 2017, 52:1308-9. 10.1016\/S0016-5085(17)34357-3","journal-title":"United European Gastroenterol J"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky E","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, et al.. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020, 145:877-84. 10.1016\/j.jaci.2019.11.025","journal-title":"J Allergy Clin Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al.. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017, 76:1340-7. 10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Heijde D","year":"2018","unstructured":"Heijde D, Baraliakos X, Gensler L, et al.. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 392:2378-87. 10.1016\/S0140-6736(18)32463-2","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde D","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al.. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019, 394:2108-17. 10.1016\/S0140-6736(19)32534-6","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, et al.. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018, 392:2441-51. 10.1016\/S0140-6736(18)31946-9","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16497","article-title":"Ixekizumab or secukinumab in psoriasis: what difference does it make?","volume":"178","author":"Paul C","year":"2018","unstructured":"Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make?. Br J Dermatol. 2018, 178:1003-5. 10.1111\/bjd.16497","journal-title":"Br J Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2510-5","article-title":"Health-related quality of life in Turkish patients with ankylosing spondylitis: impact of peripheral involvement on quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning","volume":"33","author":"Y\u0131lmaz O","year":"2013","unstructured":"Y\u0131lmaz O, Tuto\u011flu A, Garip Y, Ozcan E, Bodur H. Health-related quality of life in Turkish patients with ankylosing spondylitis: impact of peripheral involvement on quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning. Rheumatol Int. 2013, 33:1159-63. 10.1007\/s00296-012-2510-5","journal-title":"Rheumatol Int"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2020.02.006","article-title":"Health related quality of life (HRQoL) in ankylosing spondylitis patients: relation to clinical features, disease activity and radiographic damage","volume":"42","author":"Sallam RA","year":"2020","unstructured":"Sallam RA, Elbahnasawy AS. Health related quality of life (HRQoL) in ankylosing spondylitis patients: relation to clinical features, disease activity and radiographic damage. Egypt Rheumatol. 2020, 42:287-90. 10.1016\/j.ejr.2020.02.006","journal-title":"Egypt Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1613-1","article-title":"Health-related quality of life in Moroccan patients with ankylosing spondylitis","volume":"30","author":"Ibn Yacoub Y","year":"2011","unstructured":"Ibn Yacoub Y, Amine B, Laatiris A, Abouqal R, Hajjaj-Hassouni N. Health-related quality of life in Moroccan patients with ankylosing spondylitis. Clin Rheumatol. 2011, 30:673-7. 10.1007\/s10067-010-1613-1","journal-title":"Clin Rheumatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2671-x","article-title":"The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation","volume":"33","author":"Ar\u0131soy O","year":"2013","unstructured":"Ar\u0131soy O, Bes C, Cifci C, Sercan M, Soy M. The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation. Rheumatol Int. 2013, 33:1855-64. 10.1007\/s00296-013-2671-x","journal-title":"Rheumatol Int"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1616-x","article-title":"Infliximab, a TNF-\u03b1 antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level","volume":"32","author":"Ertenli I","year":"2012","unstructured":"Ertenli I, Ozer S, Kiraz S, et al.. Infliximab, a TNF-\u03b1 antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. 2012, 32:323-30. 10.1007\/s00296-010-1616-x","journal-title":"Rheumatol Int"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106325","article-title":"TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: results from a nationwide study","volume":"182","author":"Watad A","year":"2022","unstructured":"Watad A, McGonagle D, Anis S, et al.. TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: results from a nationwide study. Pharmacol Res. 2022, 182:106325. 10.1016\/j.phrs.2022.106325","journal-title":"Pharmacol Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2020_611","article-title":"Benefit of biological drugs for quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of clinical trials","volume":"1335","author":"Ta\u0144ski W","year":"2021","unstructured":"Ta\u0144ski W, \u015awi\u0105toniowska-Lonc N, Dudek K, Jankowska-Pola\u0144ska B. Benefit of biological drugs for quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of clinical trials. Adv Exp Med Biol. 2021, 1335:63-78. 10.1007\/5584_2020_611","journal-title":"Adv Exp Med Biol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study","volume":"57","author":"Davis JC Jr","year":"2007","unstructured":"Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007, 57:1050-7. 10.1002\/art.22887","journal-title":"Arthritis Rheum"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/ar2790","article-title":"Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis","volume":"11","author":"van der Heijde DM","year":"2009","unstructured":"van der Heijde DM, Revicki DA, Gooch KL, et al.. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009, 11:R124. 10.1186\/ar2790","journal-title":"Arthritis Res Ther"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.regg.2010.04.010","article-title":"[Functional level and quality of life in ankylosing spondylitis, pilot study after 16 weeks TNF blocker treatment]","volume":"45","author":"Abalos-Medina GM","year":"2010","unstructured":"Abalos-Medina GM, Ruiz-Villaverde G, S\u00e1nchez-Cano D, Ruiz-Villaverde R, Oca\u00f1a-Peinado F, Villaverde-Guti\u00e9rrez C. [Functional level and quality of life in ankylosing spondylitis, pilot study after 16 weeks TNF blocker treatment]. Rev Esp Geriatr Gerontol. 2010, 45:331-4. 10.1016\/j.regg.2010.04.010","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460310.71572.16","article-title":"Tumor necrosis factor inhibitor therapy in ankylosing spondylitis: differential effects on pain and fatigue and brain correlates","volume":"156","author":"Wu Q","year":"2015","unstructured":"Wu Q, Inman RD, Davis KD. Tumor necrosis factor inhibitor therapy in ankylosing spondylitis: differential effects on pain and fatigue and brain correlates. Pain. 2015, 156:297-304. 10.1097\/01.j.pain.0000460310.71572.16","journal-title":"Pain"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22594","article-title":"Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis","volume":"67","author":"Sieper J","year":"2015","unstructured":"Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landew\u00e9 R. Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2015, 67:1475-80. 10.1002\/acr.22594","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1837","article-title":"Effects of intravenous golimumab on health-related quality of life in patients with ankylosing spondylitis: 28-week results of the go-alive trial","volume":"23","author":"Reveille JD","year":"2020","unstructured":"Reveille JD, Deodhar A, Ince A, et al.. Effects of intravenous golimumab on health-related quality of life in patients with ankylosing spondylitis: 28-week results of the go-alive trial. Value Health. 2020, 23:1281-5. 10.1016\/j.jval.2020.04.1837","journal-title":"Value Health"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151996","article-title":"Impact of biologics on health-related quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Ho A","year":"2022","unstructured":"Ho A, Younis I, Le QA. Impact of biologics on health-related quality of life in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Semin Arthritis Rheum. 2022, 54:151996. 10.1016\/j.semarthrit.2022.151996","journal-title":"Semin Arthritis Rheum"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly","volume":"46","author":"Braun J","year":"2007","unstructured":"Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford). 2007, 46:999-1004. 10.1093\/rheumatology\/kem069","journal-title":"Rheumatology (Oxford)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/art.21330","article-title":"Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy","volume":"53","author":"Davis JC","year":"2005","unstructured":"Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum. 2005, 53:494-501. 10.1002\/art.21330","journal-title":"Arthritis Rheum"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.7889","article-title":"LB0001 dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"77","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D, Gensler LS, Deodhar A, et al.. LB0001 dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. J Ann Rheum Dis. 2018, 77:70. 10.1136\/annrheumdis-2018-eular.7889","journal-title":"J Ann Rheum Dis"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0165-3","article-title":"Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis","volume":"6","author":"Mease P","year":"2019","unstructured":"Mease P, Walsh JA, Baraliakos X, et al.. Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019, 6:435-50. 10.1007\/s40744-019-0165-3","journal-title":"Rheumatol Ther"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00536-2","article-title":"Effect of upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory ankylosing spondylitis","volume":"10","author":"Navarro-Comp\u00e1n V","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Baraliakos X, Magrey M, et al.. Effect of upadacitinib on disease activity, pain, fatigue, function, health-related quality of life and work productivity for biologic refractory ankylosing spondylitis. Rheumatol Ther. 2023, 10:679-91. 10.1007\/s40744-023-00536-2","journal-title":"Rheumatol Ther"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes IB","year":"2022","unstructured":"McInnes IB, Ostor AJ, Mease PJ, et al.. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022, 8:10.1136\/rmdopen-2021-002049","journal-title":"RMD Open"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002253","article-title":"Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Navarro-Comp\u00e1n V","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JC, Van den Bosch F, et al.. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022, 8:10.1136\/rmdopen-2022-002253","journal-title":"RMD Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172449-the-efficacy-and-safety-of-biologics-in-treating-ankylosing-spondylitis-and-their-impact-on-quality-of-life-and-comorbidities-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:48:46Z","timestamp":1709534926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172449-the-efficacy-and-safety-of-biologics-in-treating-ankylosing-spondylitis-and-their-impact-on-quality-of-life-and-comorbidities-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":75,"URL":"https:\/\/doi.org\/10.7759\/cureus.55459","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}